XKLS
SUPERMX
Market cap554mUSD
Mar 24, Last price
1.18MYR
Name
Supermax Corporation Bhd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Supermax Corporation Berhad functions as an investment holding entity, primarily focused on the production, supply, and sale of medical gloves and contact lenses within Malaysia. The company offers a diverse range of products, including various natural rubber and nitrile latex gloves, in addition to personal protective equipment. Beyond its core manufacturing activities, Supermax diversifies its operations through the trading and importation of latex gloves, sustainable biomass energy generation, the marketing and distribution of a broad spectrum of healthcare products and medical devices, and property investment ventures. Marketed under proprietary brands such as Supermax, Aurelia, and Maxter, its offerings cater to a wide clientele including laboratories, pharmacists, hospitals, physicians, and surgical professionals. With a significant international footprint, the company exports its products to approximately 165 nations worldwide, spanning key regions like the United States, the European Union, the Middle East, Asia, and the South Pacific. Established in 1987, Supermax Corporation Berhad maintains its headquarters in Sungai Buloh, Malaysia.
Key people
Rafidah Aziz
Independent Non-Executive Chairman of the Board · since 2015
Jaclyn Thai Cecile
Executive Director · since 2018
Chee Keong Tan
Executive Director · since 2018
Secretary · since 2014
Joint Company Secretary · since 2011
Geok Swee Tan
Non-Executive Director · since 2000
Cheok Saychuan
Independent Non-Executive Chairman of the Board · since 2018
Rashid Bin Bakar
Independent Non-Executive Director · since 2002
Keng Lim Ng
Independent Non-Executive Director · since 2018
Independent Non-Executive Director · since 2000
Valuation
Title MYR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||